GloriousMed Technology

About GloriousMed Technology

Established in 2015, GloriousMed Technology, also known as 仁东医学, is a specialized provider of genetic testing services and gene big data operations headquartered in Beijing, China. The company has secured significant financial backing, raising a total of $37.9 million through various funding rounds, including a Series B round in November 2021 that brought in $15.6 million. Investors include Fuzhuo Investment, 6 Dimensions Capital, and Shiyu Capital.

GloriousMed focuses on the oncology sector, providing a comprehensive suite of solutions for tumor precision immune diagnosis and treatment. The firm leverages artificial intelligence and big data analysis to develop a tumor immunotherapy evaluation system, working to establish new standards in the field. Its business model is primarily B2B, serving a network of over 1,000 hospitals and 3,000 clinical experts across 29 provinces in China. The company's services are designed to support the entire patient journey, from initial prevention and diagnosis to treatment and rehabilitation.

The company's core offering is a big data medical platform that integrates research, clinical applications, and industry development in precision immunodiagnosis. This platform develops and utilizes immunotherapy-related biomarkers to assist in clinical decision-making. While serving a broad range of oncology needs, GloriousMed has established a particular reputation in the field of urological tumors. The company operates internationally certified laboratories (including CAP accreditation) and maintains a strong research and development arm, with teams located in Beijing and a biomedical group in Suzhou responsible for IVD kit production. GloriousMed also engages in international partnerships, such as collaborations with Johns Hopkins University for medical technology exploration and Prostatype Genomics in Sweden for prostate cancer products.